A Novel Approach to Nerve-Sparing Prostate Cryosurgery

保留神经的前列腺冷冻手术的新方法

• 批准号: 7392936
• 负责人: Kristi K Snyder
• 金额: $ 19.39万
• 依托单位: CELL PRESERVATION SERVICES, INC.
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-28 至 2009-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7392936
• 关键词: Ablation; Address; Adjuvant; Affect; Anatomy; Apoptosis; Apoptotic; Area; Biological Assay; Biological Preservation; Biopsy; Biotechnology; Bladder; Blood Vessels; Cancerous; Canis familiaris; Caspase; Cell Death; Cell Survival; Cell physiology; Cells; Cessation of life; Chills; Cisplatin; Clinical; Clinical Trials; Cold Therapy; Collagen; Couples; Cryopreservation; Cryoprotective Agents; Cryosurgery; Culture Techniques; Data; Development; Device or Instrument Development; Devices; Disease; Ensure; Exposure to; Fluorescent Probes; Fluorouracil; Freezing; Future; General Hospitals; Growth; Hour; Human; In Vitro; Industry; Investigation; Lead; Malignant Neoplasms; Malignant neoplasm of prostate; Marketing; Medical; Methods; Microscopy; Modeling; Molecular; Molecular Analysis; Monitor; Morbidity - disease rate; Nerve; Neurons; Organ; Pathway interactions; Patients; Pattern; Phase; Physicians; Physics; Play; Procedures; Process; Prostate; Prostate Cancer therapy; Protective Agents; Protocols documentation; Purpose; Recovery; Role; Role playing therapy; Series; Services; Solutions; Staging; Stress; Structure; Supporting Cell; Technology; Temperature; Testing; Therapeutic; Time; Tissue Engineering; Tissues; Treatment Protocols; Urethra; Western Blotting; anticancer research; base; cancer cell; cancer therapy; cell type; cold temperature; concept; day; design; improved; inhibitor/antagonist; innovation; medical schools; neuron loss; novel; novel strategies; novel therapeutics; rectal; relating to nervous system; response

DESCRIPTION (provided by applicant): Cell Preservation Services Inc. (CPSI) is a biotechnology corporation focused on developing new and innovative approaches to the use of chilling and freezing temperatures in support of the cell therapy and cancer arenas. In the former, CPSI studies stress pathways activated during hypothermic storage (4C) and cryopreservation (-196) so that improved processes can be developed. Similar data on stress pathways are also being used to potentiate cell death in cancer cells during ablative freezing processes - a regime that couples traditional cryosurgery with adjuvant (e.g. 5-FU, cisplatin) treatments. This approach has recently led to the initiation of a physician sponsored IND for the treatment of advanced stage prostate cancer. This Phase I project proposes to develop a novel therapeutic device (Neuprosol") for the protection of the neural vascular bundles (NVB) and ultimately erectile function during the cryosurgical treatment of prostate cancer. The reasoning behind the development of the device are as follows: (1) NeuprosolTM will be applied directly to the NVB at the time of the cryosurgical application; (2) The protective agents will be designed through molecular analysis to be nerve cell specific; (3) The agents will also be developed to provide varying levels of zonal (thermal) protection; (4) The utilization of this device will be an effective nerve-sparing agents and may also eventually be applied for urethral protection. The Specific Aims of the Phase 1 are: SA1 Determine the effects of freezing on nerve cell viability; SA2 Determine the role played by apoptosis in freezing-induced cell death of neuronal cells; SA3 Determine which novel agents can be used to protect nerve cells from the destructive mechanisms of freezing; SA4 Test the efficacy of NeuprosolTM as a nerve-sparing concept using a canine cryosurgical model. Successful completion of Phase I and 2 will lead to the development of NeuprosolTM which can then be used as an effective nerve-sparing agent during cryosurgical ablation of prostate cancer. Once developed and tested, NeuprosolTM may become useful as a nerve-sparing treatment as well as an alternative method for protecting other tissues, such as the urethra. Consequently, this novel therapeutic design will provide a major benefit to the clinical area as well as provide a platform for future development of therapeutic strategies for the treatment of cancer.

描述（由申请人提供）：Cell Preservation Services Inc. (CPSI) 是一家生物技术公司，致力于开发利用冷冻和冷冻温度支持细胞治疗和癌症领域的创新方法。在前者中，CPSI 研究低温储存 (4C) 和冷冻保存 (-196) 期间激活的应激途径，以便开发改进的工艺。有关应激途径的类似数据也被用于在消融冷冻过程中增强癌细胞的细胞死亡，这是一种将传统冷冻手术与辅助（例如 5-FU、顺铂）治疗相结合的方案。这种方法最近导致了一项由医生赞助的用于治疗晚期前列腺癌的 IND 的启动。该一期项目拟开发一种新型治疗装置（Neuprosol”），用于在前列腺癌冷冻手术治疗过程中保护神经血管束（NVB）并最终保护勃起功能。开发该装置的理由如下：（1）NeuprosolTM将在冷冻手术时直接应用于NVB；（2）将设计保护剂 通过分子分析确定神经细胞特异性； (3) 还将开发药剂以提供不同级别的区域（热）保护； (4)该装置的使用将成为一种有效的神经保护剂，并且最终也可能应用于尿道保护。第一阶段的具体目标是： SA1 确定冷冻对神经细胞活力的影响； SA2 确定冷冻诱导细胞凋亡的作用 神经元细胞死亡； SA3 确定哪些新型药物可用于保护神经细胞免受冷冻破坏机制的影响； SA4 使用犬类冷冻手术模型测试 NeuprosolTM 作为神经保护概念的功效。第一阶段和第二阶段的成功完成将导致 NeuprosolTM 的开发，该药物可在前列腺冷冻手术消融过程中用作有效的神经保留剂 癌症。一旦开发和测试完成，NeuprosolTM 可能会成为一种有用的神经保护治疗方法以及保护其他组织（例如尿道）的替代方法。因此，这种新颖的治疗设计将为临床领域带来重大益处，并为未来开发癌症治疗策略提供平台。